Eric Matthew Jurgens

7PUBLICATIONS
49CO-AUTHORS
Haematological tumoursMedical bacteriologyPredictive and prognostic markersMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 29, 2026
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma.

|Jul 20, 2026
Lenalidomide-Related Diarrhea in Patients with Multiple Myeloma is Associated with Gut Microbiota Dysbiosis and Disruption of the Bile Acid Pool.

|Jun 17, 2026
CAR T cells take on precancers.

|Apr 12, 2026
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma.

Hamza Hashmi, Tara Sebastian, Sridevi Rajeeve

|Aug 25, 2025
Immune MRD Status Informs Tumor MRD Outcome Prognostication in Patients with Multiple Myeloma on Lenalidomide Maintenance.

Ross S Firestone, Anish K Simhal, Devin McAvoy

|Dec 04, 2024
Phase I Trial of MCARH109, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma: An Updated Analysis.

Eric M Jurgens, Ross S Firestone, Jagrutiben Chaudhari

Pageof 2

Frequent Collaborators

6 joint publications

Sham Mailankody

5 joint publications

Heather J Landau

5 joint publications

Gunjan L Shah

5 joint publications

Saad Z Usmani